Colorectal Cancer

Tanios Bekaii-Saab, MD, explains the barriers to molecular testing for patients with metastatic colorectal cancer, and how they can be addressed.

A panel of expert oncologists consider how HER2 expression can positively impact the selection of targeted therapies for patients with metastatic colorectal cancer.

Expert perspectives on the PARADIGM study, which highlighted the role of panitumumab in combination with frontline chemotherapy in patients with left-sided, RAS wild-type metastatic colorectal cancer.

Elle Charnisky describes her experience with molecular testing, and Nurse Practitioner Deanna Griffie details how she explains testing to patients with metastatic colorectal cancer.

Shared insight on the optimal use of circulating tumor DNA and minimal residual disease in the identification and management of metastatic colorectal cancer.

Opening their discussion on metastatic colorectal cancer management, expert panelists reflect on the molecular testing paradigm in the setting of diagnosis and workup.

Dr Tanios Bekaii-Saab explains the rarity of HER2+ metastatic colorectal cancer and how his clinical practice detects HER2 alterations.

Takayuki Yoshino, MD, PhD, spoke about the benefit of panitumumab vs bevacizumab in combination with mFOLFOX6 in the frontline treatment of patients with RAS wild-type metastatic colorectal cancer.

Patient Elle Charnisky shares the symptoms that led to her diagnosis of HER2+ metastatic colorectal cancer, and the online resources she used for education after.

Tanios Bekaii-Saab, MD, provides a brief overview of the typical presentation and diagnosis of metastatic colorectal cancer.

For patients with colon cancer, 3-month treatment with mFOLFOX6 or CAPOX improved safety outcomes without affecting efficacy vs 6-month treatment, according to data from the phase 3 ACHIEVE trial.

Opioid use disorder and overdose are important risks to consider in older patients diagnosed with stage II/III colorectal cancer, especially those who were opioid naïve.

Ardaman Shergill, MD, and Aparna Raj Parikh, MD, explore ongoing clinical investigations evaluating the use of circulating tumor DNA in the treatment of early-stage colon cancer.

Ben Fangman, MD, and colleagues provide an overview of the use of circulating tumor DNA levels to detect minimal residual disease in colorectal cancer.

Data from the phase 3 SUNLIGHT study highlighted the increased survival benefit of trifluridine/tipiracil plus bevacizumab compared with trifluridine/tipiracil alone for the treatment of metastatic colorectal cancer.

Patients with metastatic colorectal cancer who were below a certain income level appear to be more susceptible to major financial hardship.

Chiara Cremolini, MD, PhD, discussed results from the phase 3 TRIPLETE study of triplet chemotherapy plus panitumumab in previously untreated patients with RAS/BRAF wild-type unresectable metastatic colorectal cancer.

Patients with previously treated, metastatic, HER2-positive colorectal cancer may benefit from treatment with tucatinib and trastuzumab, which was granted priority review by the FDA.

Based on findings from a real-world retrospective analysis, Stacey A. Cohen, MD, discussed the prognostic value of post-surgical minimal residual disease detection in patients with stage I to III colorectal cancer.

Findings from the phase 1b/2 KRYSTAL-1 trial showed encouraging responses with adagrasib in patients with advanced KRAS G12C-mutant colorectal cancer.

Patients with mismatch repair deficient (dMMR) colon cancer experienced a high rate of major pathologic complete response following treatment with nivolumab and ipilimumab for 4 weeks.

Tucatinib as monotherapy and in combination with trastuzumab supported further investigation of the regimens in patients with metastatic HER2-positive colorectal cancer.

At the 2022 ASCO Annual Meeting, Christine Parseghian, MD, reviewed results from a phase 2 trial assessing efficacy of panitumumab plus or minus trametinib in patients with RAS/BRAF wild-type colorectal cancer and compared EGFR rechallenge strategies with available agents in the third-line setting.

Results from the phase 2 ExIST trial indicated that the addition of galunisertib to neoadjuvant chemoradiotherapy for patients with locally advanced rectal cancer resulted in an improvement in responses.

Three months of neoadjuvant chemotherapy may downstage early-stage rectal cancer and thereby reduce the need for total mesorectal excisions (TMEs), resulting in higher rates of organ preservation.

Christine Parseghian, MD, discussed the effects of rechallenging patients with a prior response to EGFR inhibition with panitumumab plus or minus the MEK inhibitor trametinib in RAS/BRAF wildtype, microsatellite stable colorectal cancer.

Cornelis J. A. Punt, MD, PhD, spoke about bevacizumab plus either FOLFOXIRI or FOLFOX/FOLFIRI in patients with unresectable colorectal liver metastases and right-sided or RAS/BRAF-mutant tumors and how these regimens may be used for curative-intent therapy.

Expert oncologists look toward future utilization of circulating tumor DNA testing and consider how the field of oncology may evolve.

Shared insight on how circulating tumor DNA may be used in real-world clinical practice to improve the value of cancer care.

Data from the phase 2 DYNAMIC trial show that a circulating tumor DNA–guided approach to adjuvant therapy selection may be feasible for patients with stage II colorectal cancer, but Tanios S. Bekaii-Saab, MD, is skeptical about its readiness for prime time.